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TO THE EDITOR Expression of multidrug resistance (MDR) proteins is a major obstacle in the treatment of acute myeloid leukemia (AML). In fact, the MDRphenotype has been associated with lower remission rates and shorter overall survival in AML patients. 1 Central nervous system (CNS) involvement is also currently considered as an adverse prognostic factor for AML, since conventional therapies are poorly effective and new strategies are not clearly identified.
Acute promyelocytic leukemia, AML-M3 subtype or APL, characterised by anomalies of the ␣-trans-retinoic acid receptor, is the only AML subtype that never presents MDR over-expression. This form is particularly sensitive to the combination of idarubicin (Ida) and ␣-trans-retinoic acid (ATRA), with very high complete remission (CR) rates. 2 The rare cases resulting refractory to induction therapy are characterised by poor prognosis, as alternative treatments have, up to now, not been established.
Liposomal daunorubicin (DaunoXome or DNX   . , Gilead Science, Foster City, CA, USA) has shown more efficacy than free daunorubicin against multidrug resistance cell lines, 3 lower toxicity profile 4 and, in particular, capability to overcome the blood-brain barrier. We thus administered DNX plus cytosine-arabinoside to an early relapsed MDR+ AML and to an APL refractory patient, both with meningeal involvement.
The first case refers to a 36-year-old female, diagnosed for AML M4 subtype in March 2000. Two adverse prognostic factors were present at diagnosis: hyperleukocytosis (200 × 10 /day, days 1-5) was administered. NMR and bone marrow aspirate documented a CR, on day 14 and 21 from the end of chemotherapy respectively, still persisting after 13 months.
The second case refers to a 37-year-old male, diagnosed for APL. Hyperleukocytosis (70 × 10 9 /l) was present at diagnosis. Induction regimen, based on idarubicin and ATRA, followed by three consolidation courses (induction therapy: 45 mg/m 2 /day ATRA were administered orally until the achievement of CR or for a maximum of 90 days, with four 12 mg/m 2 doses of Idarubicin given intravenously (i.v.) on days 2, 4, 6 and 8; consolidation: AraC 1 g/m 2 , for 5 days) were administered, inducing molecular CR. After induction therapy, stem cell transplantation was performed, as both patients were in CR. The first one is still in CR (13 months); the second one died from infection, still in CR, after 4 months.
Anthracyclines are the reference drugs for treatment of AML, but a few factors limit their use and effectiveness. One element is toxicity, especially mucosal (oral and intestinal) and cardiac. This factor limits the administration of the drug particularly in relapsed or resistant patients, heavily pre-treated or patients who are candidates for BMT. In addition, the over-expression of MDR proteins reduces the intracellular concentration of anthracyclines, that are pumped out across the cell membrane. Moreover, these drugs do not reach adequate concentrations in the central nervous system (CNS), being ineffective against disease at this level. In our first report, the patient presented a very atypical localisation. In fact AML blasts can involve CNS in about 10% of cases at relapse, but isolated cerebellar leukemic meningitis has not been definitely described. DaunoXome is a special liposomal formulation of daunorubicin, entrapped into small liposomes. This combination increases blastic cells exposure by protecting the intracellular drug from transporter proteins. This leads to lower toxicity against normal tissues and increases efficacy against tumor cells. Furthermore, DNX overcomes the blood-brain barrier, being effective also in CNS diseases such as gliomas/glioblastomas, astrocytomas, medulloblastomas, ependymomas, craniopharyngiomas and lymphomas. 5 Only few data are available regarding the efficacy of DNX in poor risk acute leukemia 6 and, in particular, no data about DNX effectiveness against CNS myeloid leukemia have been reported before, so this is the first demonstration of DNX efficacy in CNS AML. Moreover, this is the first report regarding effectiveness of DNX in APL and its ability to induce molecular remissions in ATRA resistant patients as well.
We conclude that DaunoXome seems thus to be a useful drug for poor risk AML with CNS involvement. Further studies are warranted in order to establish its definitive role.
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Human T cell lymphotropic virus type-1 (HTLV-1), the first human retrovirus to be discovered, causes adult T cell leukemia/lymphoma (ATLL). HTLV-1 infection, like human immunodeficiency virus (HIV) infection, leads to immunodeficiency in the hosts, especially in patients who develop ATLL; ATLL patients are susceptible to opportunistic infections and are at an increased risk of other malignancies. ATLL is an aggressive peripheral T cell neoplasia with unique clinical features such as skin involvement and hypercalcemia. The incidence of ATLL is high in southwestern Japan, particularly in Okinawa.
Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcomaassociated herpesvirus, was first detected in Kaposi's sarcoma (KS) tissues from acquired immunodeficiency syndrome (AIDS) patients. 1 Subsequently, the virus has been associated with all forms of KS (classic, iatrogenic, endemic, and AIDS-associated), primary effusion lymphoma, and a subset of multicentric Castleman's disease. KS is rare in Asia, even in patients with AIDS, but the incidence of KS not associated with HIV infection is high in Okinawa. 2 Although some cases of KS associated with ATLL have been reported, no study has yet been reported describing the increased rate of HHV-8 infection in ATLL patients.
In this study, we measured HHV-8 antibodies in 84 ATLL patients and 264 patients with other hematological diseases in Okinawa between 1990 and 2000 to observe the possible association between HHV-8 infection and ATLL. HHV-8 antibodies in plasma samples The mean of optical density of plasma samples obtained from 10 blood donors plus 5 standard deviations was used as a cut-off value. Sera taken from two KS patients and a normal person, used as positive and negative control respectively, were included in each assay. We also studied 200 HTLV-1-positive and 1079 HTLV-1-negative plasma samples collected from general blood donors in the Japanese Red Cross Okinawa Blood Center. Anti-HHV-8 antibodies were positive in two (2.4%) of the 84 ATLL patients (Table 1) : a 59-year-old female of lymphoma type and a 58-year-old female of acute type ATLL, according to Shimoyama classification, 4 showed positive anti-HHV-8 antibodies on ELISA. Both patients were native Okinawans. We also investigated the presence of HHV-8, Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6), HTLV-1 and HIV in peripheral blood mononuclear cells of both patients, using polymerase chain reaction (PCR) techniques. Patient No. 1 was positive for HTLV-1, EBV and HHV-6, but negative for HHV-8, while patient No. 2 was positive for HTLV-1, HHV-8 and EBV, but negative for HHV-6 ( Figure 1 ). Neither of them was positive for HIV (data not shown). Despite combination chemotherapy (cyclophosphamide, adriamycin, vincristine, prednisolone, bleomycin, and etoposide), they expired due to disease progression without symptoms related to these herpesviruses.
Anti-HHV-8 antibodies were found in two of 264 patients with other hematological diseases: a 86-year-old HTLV-1-positive female with myelodysplastic syndrome and a 71-year-old HTLV-1-negative male with non-Hodgkin's lymphoma. In general blood donors, anti-HHV-8 antibodies were detected in one (0.5%) of 200 HTLV-1-positive persons and one (0.1%) of 1079 HTLV-1-negative persons. The rate of HHV-8 infection in ATLL patients was significantly higher than in the general blood donors (P ϭ 0.01, Fisher's exact probability test), indicating an increased risk of HHV-8 infection in patients with ATLL.
In summary, we conclude that the prevalence of anti-HHV-8 antibodies in patients with ATLL is higher than in other populations and multiple viral infections observed in two ATLL patients, may be explained by the functional impairment of T cells. According to Nakamura et al, 5 CD4-positive lymphocytes, infected with HIV or HTLV-1, secrete a potential mitogen which stimulates the growth of KS. Thus, our present findings suggest an increased risk of KS in patients with ATLL.
